Characteristics of patients best treated with high dose chemotherapy/hematopoietic stem cell transplantation (HDC/HSCT) for relapse of Hodgkin’s lymphoma after primary chemotherapy.
| Definite |
| Relapse < 1 year after completion of primary chemotherapy |
| Relapse with B symptoms |
| Relapse in extranodal sites |
| Relapse in previously irradiated sites |
| Controversial but probably indicated |
| Relapse only in previously unirradiated lymph nodes, in the absence of B-symptoms, occurring > 1 year after completion of primary chemotherapy |
| Definite |
| Relapse < 1 year after completion of primary chemotherapy |
| Relapse with B symptoms |
| Relapse in extranodal sites |
| Relapse in previously irradiated sites |
| Controversial but probably indicated |
| Relapse only in previously unirradiated lymph nodes, in the absence of B-symptoms, occurring > 1 year after completion of primary chemotherapy |